Reaction

Eye Operation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,467 reports · 99 co-occurring drugs

As of the last recalculation, Eye Operation appears in 4,467 FAERS reports alongside 99 co-occurring drug terms. The strongest observed disproportionality signal is CARBOXYMETHYLCELLULOSE SODIUM (PRR 37.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Carboxymethylcellulose Sodium	74	37.3	37.6
Cenegermin-Bkbj	64	25.0	25.1
Prednisolone Acetate	39	17.7	17.8
Aflibercept	113	17.3	17.3
Brimonidine Tartrate	44	11.6	11.6
Upadacitinib	162	9.6	9.6
Dorzolamide Hydrochloride And Timolol Maleate	16	9.5	9.5
Ibrutinib	153	9.1	9.1
Risankizumab-Rzaa	152	8.9	8.9
Brinzolamide	15	8.1	8.1
Latanoprost	84	7.9	7.9
Bimatoprost	47	7.7	7.7
Losartan Potassium And Hydrochlorothiazide	19	7.7	7.7
Timolol Maleate	15	7.1	7.1
Moxifloxacin	17	5.6	5.6
Calcium, Magnesium, Potassium, And Sodium Oxybates	10	5.4	5.4
Moxifloxacin Hydrochloride	23	5.3	5.3
Insulin Degludec	26	5.2	5.2
Timolol	13	5.0	5.0
Ranolazine	11	4.9	4.9
Valsartan And Hydrochlorothiazide	14	4.8	4.8
Patiromer	14	4.7	4.7
Insulin Human	39	4.6	4.6
Insulin Glargine	233	4.6	4.6
Oral Semaglutide	71	4.6	4.6
Erythromycin	18	4.5	4.5
Atropine Sulfate	10	4.3	4.3
Insulin Aspart	60	4.3	4.3
Human Insulin	11	4.1	4.1
Faricimab	7	4.0	4.0
Atropine	7	3.9	3.9
Fluticasone Furoate	10	3.9	3.9
Pancrelipase	31	3.8	3.8
Lifitegrast	13	3.7	3.7
Umeclidinium	7	3.6	3.6
Fluticasone Furoate And Vilanterol Trifenatate	26	3.4	3.4
Fluticasone Propionate And Salmeterol	30	3.4	3.4
Relugolix	17	3.4	3.4
Umeclidinium Bromide And Vilanterol Trifenatate	12	3.4	3.4
Bimekizumab	15	3.3	3.3
Niacin	8	3.2	3.2
Oxybutynin Chloride	6	3.2	3.2
Bosentan	34	3.2	3.2
Linaclotide	18	3.2	3.2
Avapritinib	8	3.1	3.1
Mepolizumab	31	2.9	2.9
Rotigotine	9	2.9	2.9
Alirocumab	15	2.8	2.8
Nintedanib	18	2.7	2.7
Armodafinil	12	2.7	2.7
Ranibizumab	15	2.6	2.6
Macitentan	38	2.6	2.6
Tolvaptan	8	2.6	2.6
Vigabatrin	8	2.6	2.6
Tiotropium Bromide Inhalation Spray	6	2.5	2.5
Tofacitinib	94	2.4	2.4
Selexipag	13	2.3	2.3
Insulin Lispro	69	2.3	2.3
Vibegron	4	2.3	2.3
Niraparib	11	2.3	2.3
Sodium Oxybate	32	2.3	2.3
Abatacept	65	2.2	2.2
Certolizumab Pegol	55	2.2	2.2
Icosapent Ethyl	4	2.2	2.2
Golimumab	40	2.2	2.2
Travoprost	4	2.2	2.2
Riociguat	15	2.1	2.1
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	19	2.1	2.1
Palbociclib	43	2.1	2.1
Rasagiline Mesylate	5	2.1	2.1
Testosterone Cypionate	4	2.1	2.1
Bosutinib	4	2.1	2.1
Eptinezumab-Jjmr	4	2.0	2.0
Etanercept	239	1.9	1.9
Voxelotor	9	1.9	1.9
Rimegepant Sulfate	5	1.8	1.8
Ambrisentan	48	1.8	1.8
Belimumab	12	1.8	1.8
Teriparatide	42	1.7	1.7
Romosozumab-Aqqg	5	1.7	1.7
Denosumab	73	1.7	1.7
Evolocumab	57	1.6	1.6
Venetoclax	21	1.6	1.6
Apalutamide	4	1.6	1.6
Brivaracetam	3	1.6	1.6
Cariprazine	3	1.5	1.5
Dupilumab	150	1.5	1.5
Onabotulinumtoxina	24	1.5	1.5
Teriflunomide	14	1.4	1.4
Brexpiprazole	5	1.4	1.4
Tafamidis	3	1.2	1.2
Exenatide	13	1.2	1.2
Sarilumab	6	1.1	1.1
Palivizumab	3	0.9	0.9
Guselkumab	5	0.7	0.7
Droxidopa	3	0.6	0.6
Pimavanserin Tartrate	7	0.6	0.6
Valbenazine	3	0.6	0.6
Cinacalcet Hydrochloride	5	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.